Biomira receives positive DSMB recommendation

Biomira (TSE:BRA; BIOM) said the U.S. Data Safety Monitoring Board (DSMB), after reviewing 12-week data from the first 300 patients, recommended the company continue its Phase III trial of Theratope v...